Inovio, Biogen Idec, and Gilead Sciences

Inovio got some good data, and you can read my interpretation at Seeking Alpha:

Is Inovio Undervalues after Positive HPV Therapy Results?

I've been listening to results conferences for the stocks I either own or would like to own. Two somewhat related, at least being biotechnology stocks with disease therapies, are:

Gilead Sciences (GILD) Q2 analyst conference

Gilead had outstanding results, largely based on Sovaldi, a cure for Hepatitis C. I believe Gilead should be heading to $180 or so a share. I'm not sure whose selling at $90, maybe people who bought way back when at $5 and have to reallocate, but probably people with some hope that some other drug will knock out Sovaldi, a hope that will be crushed as we move through the quarters. Gilead is generating so much cash it can use for buy backs, fighting that tide is the height of folly.

Biogen Idec (BIIB) Q2 analyst conference

Biogen has been performing great and raised guidance. In this case the stock did go up substantially following the report. It is not a cheap stock, but if you look down the road, it is highly likely to keep up a rapid pace of profit growth for years to come.